• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.14
  • VXN 24.38
  • VXO 19.94
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
ENZ (Enzo Biochem Inc. ($0.01 Par Value))
Last Trade 3.08 Dividend/Share 0 PE Ratio -28
Date November 16-2018 Dividend Yield 0.000 Return on Assets -9.86
Change -0.1 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.21 Price/Sale 1.966
Ask null LatestEPS Date 2018-07-31 Price to Book 1.85
Volume null EPS ttm -0.11 Institutional % 61.1
Avg Volume 0.15M Shares Outstanding 47.18M Insider % 14.2
Open 3.15 Float 40.47M Short Ratio 4.310
Prev Close 3.18 Return On Equity -12.14 5 Year Change % 0.305
High 3.24 Consensus EPS 0 2 Year Change % -0.552
Low 3.06 No. of Estimate 0.000 1 Year Change % -0.662
52 Week High 9.87 EPS Surprise $ null YTD Change % -0.627
52 Week Low 3.05 EPS Surprise Percent 0 6 Month Change % -0.546
52 Week Change -66.558 EBITDA 0.11M 3 Month Change % -0.243
50 Day MA 3.7946 Revenue 27.68M 1 Month Change % -0.183
200 Day MA Gross Profit 12.25M 5 Day Change % -0.034
Market Cap 145.32M Cash 66.85M 30 Day Change % -0.220
Beta 1.333343 Debt 0M Stock Exchange New York Stock Exchange
Sector Healthcare Revenue Per Share 1 Short Interest 865981
Short Date 2018-10-31 Revenue Per Employee 55022 Short Ratio 4.310
Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.